Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generic Drug Review At US FDA: Has Submission Rush Ended Or Just Paused?

Executive Summary

Excitement to get a 10-month ANDA review may have waned in January as submissions plummet, but can approvals keep up?

You may also be interested in...



ANDA Stress Test: End-Of-Year Submission Bolus Pressures US FDA Review System

As more generic applications arrive, Office of Generic Drugs staff may have a tougher time reaching review goals.

Generic Application Quality Showing Signs Of Improvement

US FDA’s monthly refuse-to-receive numbers for ANDAs are down early in FY 2017, suggesting that sponsor have an increased understanding of the agency’s standards.

Another ANDA Submission Surge Begins

US FDA receives more than 100 ANDAs during the first month of GDUFA year five, suggesting sponsors want the new 10-month review goal and cheaper user fee.

Related Content

Topics

UsernamePublicRestriction

Register

GB002006

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel